Analytical Data
-
Gene name
STEAP1
- Application
-
Alternative Names
Six-transmembrane epithelial antigen of prostate 1
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UHE8
-
Expression Region
1-339aa
-
Molecular Weight
58.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1) is a transmembrane protein originally identified as a prostate-specific antigen, predominantly expressed in prostate tissues and several other malignancies. Its role extends beyond mere cell surface expression, as it is implicated in various cellular processes, including tumor progression and angiogenesis. STEAP1 has gained significant attention in cancer research due to its potential as a biomarker and therapeutic target, especially in prostate cancer. Research has demonstrated that STEAP1 can actively participate in the reduction of iron ions, suggesting a role in cellular iron homeostasis and metabolism. The recombinant expression of STEAP1 provides an opportunity to further investigate its function, mechanisms of action, and interactions with other signaling pathways in cancer biology. Moreover, the study of STEAP1 as a recombinant protein can facilitate the development of targeted therapies, antibody-based treatments, and imaging agents for tumor detection, particularly as STEAP1 shows differential expression in cancerous tissues versus normal tissues. This presents a promising avenue for developing novel diagnostic and therapeutic strategies aimed at improving patient outcomes in prostate cancer and potentially other malignancies expressing STEAP1. The growing body of research surrounding STEAP1 underscores the significance of understanding its molecular characteristics and biological implications, paving the way for advanced therapeutic interventions in oncology.
